We are a clinical stage biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.
We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.
We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.
Feb 19, 2020 10:25 AM EST
Copyright West LLC. Minimum 15 minutes delayed.
News and Events
NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)Read more
NGM Bio Announces Appointment of Shelly Guyer to Board of DirectorsRead more
NGM Bio to Present at the Stifel 2019 Healthcare ConferenceRead more
More events are coming soon.